I
ndigenous Australian individuals have lower life expectancy compared with the Australian population as a whole, 1 especially in remote central Australia, where they experience the worst social disadvantage 2 and morbidity in the country. Health care professionals in these areas struggle to deliver adequate services owing to the logistics involved. As a result, increased resources are always required but not always received. It is therefore important to highlight the needs of this underrepresented population by drawing the attention of policy makers to the adverse outcomes experienced in remote regions of Australia.
The assoc iation of v isual impairment (VI) w ith increased mortality rate has been reported in many places across the world including Australia. 3, 4 However, to our knowledge, this important association has not been demonstrated among indigenous Australian individuals, which, if present, may help to direct service provision and funding. We aimed to assess the association between VI and mortality among indigenous Australian individuals within remote central Australia.
Methods
The Central Australian Ocular Health Study took place in remote communities within central Australia and included a total target population of 2014 persons 40 years and older. 5, 6 Ophthalmic clinics were held at 30 of the largest communities between July 2005 and June 2008. Patients were recruited from those who identified themselves as indigenous Australian. Ethical approval from the Central Australian Human Research Ethics Committee was obtained, and the study conformed to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participants, using an interpreter where necessary. Visual acuity (VA) was determined using a tumbling E acuity chart at 3 m in a well-lit room. If the patient could not read the top letter (6/120 equivalent), they were recorded as either counting fingers at 2 m or 1 m, hand movements, light perception, or no light perception. Visual impairment was defined as a VA of less than 6/12 in the better eye.
Patients were then followed up in these remote clinics during the subsequent 10 years. Mortality and the cause of mortality for those 40 years or older at the time of recruitment was established by accessing records from Alice Springs Hospital, Alice Springs, Northern Territory, and the Department of Births, Deaths, and Marriages from South Australia.
Statistical Analysis, System 9.1 (SAS Institute Inc) was used for statistical analysis including descriptive statistics, t test, and Cox proportional hazards model. Age was considered as a continuous variable. Sex, VI, blindness, hypertension, and diabetes were considered as categorical variables. Test statistics, 95% confidence intervals, and P values are presented. A P value of less than .05 was considered statistically significant, and all P values were 2-sided.
Results
We recruited 1347 of 2014 individuals in the target population during the 36-month period. Ninety patients were lost to followup, with 1257 patients (93%) remaining. This included 476 men (37.9%) and 781 women (62.1%), and the mean (SD) age was 56 (11) years (t = 0.63; P = .53). The median time for patient followup in the remote clinics was 8.7 years (interquartile range, 7.8-9.5 years ), with 377 patients (30%) followed up for more than 9 years.
At the end of 10 years, all-cause mortality was found to be 29.3% ( Figure) . Of those with VA of 6/12 or better, 21.1% were deceased. However, this increased for those with reduced VA: 49.0% (95% CI, 39.6% to 58.4%) for VA of less than 6/12 to 6/60 (P < .001) and 44.7% (95% CI, 26.1% to 63.3%) for VA less than 6/60 (P < .001). There was no difference in 10-year all-cause mortality for those with VA of less than 6/12 to 6/60 and VA of less than 6/60 (difference of 4.3%; 95% CI, −23.7% to 32.3%; P = .69). Therefore, all patients who had VI were considered as a single group, which had a 10-year all-cause mortality rate of 48.5%. After multivariate adjustment for age, sex, diabetes, and hypertension, the VI group was 40% more likely to die during the 10 years of follow-up (hazard ratio [HR], 1.40; 95% CI, 1.16 to 1.70; P = .001) ( Table 1) . Causes of death could be established in 58% of those who died. The causes of death among the VI group were also analyzed ( Table 2) . Visual impairment was associated with increased renal-related mortality (HR, 1.85; 95% CI, 1.11 to 3.06; P = .02) after multivariate adjustments.
Discussion
This study found that among indigenous Australian individuals within central Australia, VI at baseline was strongly correlated with higher mortality, which is consistent with what has been found in other populations. 3, 4, 7 Those with VI had 40% higher mortality during the 10-year follow-up period compared with those with normal vision. Although this is similar to that found in other studies, 3 the 10-year mortality rate among indigenous Australian individuals with visual impairment (48.5%) was 3 times that of the Australian population as a whole (13.7%).
8,9
Key Points Question What is the association of visual impairment (visual acuity worse than 6/12) with mortality risk among indigenous Australian individuals in remote central Australia, who experience the worst social disadvantage and morbidity in the country?
Findings In this cohort study of 1347 remote indigenous Australian individuals, vision impairment was associated with 40% higher 10-year mortality after adjusting for age, sex, hypertension, and diabetes compared with normal vision.
Meaning Visual impairment is associated with an increased mortality among remote indigenous Australian individuals, which is 3 times higher than that of the general population; efforts must be made to improve the ocular health of this highly disadvantaged group. Declining VA may be a marker of frailty, biological aging, and predictors of mortality, 10 with individuals having poorer mobility and physical function 7 and at higher risk of falls, accidents, and subsequent health complications. 4 Visual impairment is tied strongly to independence, 11, 12 which is linked to cognitive decline and also with adverse psychosocial effects such as isolation and depression, all of which have been linked to higher mortality. 12, 13 We showed that VI is associated with increased renalrelated mortality, similar to that found among hemodialysis patients with VI. 14 The prevalence of VI is higher among patients with chronic renal disease, partly owing to sharing of common systemic risk factors such as hypertension, diabetes mellitus, and smoking. 15 
Limitations
Our study is limited by the method through which the sample was recruited. The study recruited patients for 3 years and sampled 67% of the target population. Because patients needed to voluntarily present to an eye clinic, there is the potential that the prevalence of VI within this sample may have been overrepresented, and that this cohort may have had more health problems than the remaining 33% of the population, which might lead to an overestimation of the association between VI and mortality. However, visits to these remote communities occurred only once or twice per year; therefore, the health workers in the communities would actively encourage every resident to attend the clinics regardless of their symptoms. Ninety-five percent of patients presented because of diabetes (regardless of symptoms), because of presbyopia, or without any symptoms. We therefore feel that because most presented for a checkup because the clinic was available and not because of symptoms, the data collected should reflect an accurate estimate of mortality and its association with VI within this indigenous population. Because the study was unfunded and took place in remote indigenous Australian communities, it was necessary that it occur in the context of service provision, which limited the ability to collect data of other potential confounding covariates such as mobility, mental health status, smoking and socioeconomic status; therefore, these could not be included in the analysis. In addition, the study was only powered to detect the prevalence of conditions that lead to VI and not to detect the effect of each of these conditions on mortality. We therefore reported the effect of VI on mortality because this can not only affect mortality directly via its cause (eg, diabetes) but also have indirect effects on mortality such as by increasing the risks of falls and depression.
Conclusions
Visual impairment was associated with 40% (95% CI, 16%-70%) higher 10-year mortality risk. These data suggest it is important to have provision of comprehensive ophthalmic health care to remote indigenous Australian individuals as part of a collaborative effort to close the gap in morbidity and mortality outcomes. Probability of Survival, % 
